☰

Michelle L. VanLith, Ph.D. - Publications

Affiliations: 
2001 University of Nebraska Medical Center, Omaha, NE, United States 
Area:
Immunology
Tree Info Similar researchers PubMed Report error

8 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2006 Moniaux N, Nemos C, Schmied BM, Chauhan SC, Deb S, Morikane K, Choudhury A, Vanlith M, Sutherlin M, Sikela JM, Hollingsworth MA, Batra SK. The human homologue of the RNA polymerase II-associated factor 1 (hPaf1), localized on the 19q13 amplicon, is associated with tumorigenesis. Oncogene. 25: 3247-57. PMID 16491129 DOI: 10.1038/Sj.Onc.1209353  0.462
2004 Kohlgraf KG, Gawron AJ, Higashi M, VanLith ML, Shen X, Caffrey TC, Anderson JM, Hollingsworth MA. Tumor-specific immunity in MUC1.Tg mice induced by immunization with peptide vaccines from the cytoplasmic tail of CD227 (MUC1). Cancer Immunology, Immunotherapy : Cii. 53: 1068-84. PMID 15696607 DOI: 10.1007/S00262-004-0557-1  0.728
2002 VanLith ML, Kohlgraf KG, Sivinski CL, Tempero RM, Hollingsworth MA. MUC1-specific anti-tumor responses: molecular requirements for CD4-mediated responses. International Immunology. 14: 873-82. PMID 12147624 DOI: 10.1093/Intimm/Dxf053  0.622
2002 Sivinski CL, Kohlgraf KG, VanLith ML, Morikane K, Tempero RM, Hollingsworth MA. Molecular requirements for CD8-mediated rejection of a MUC1-expressing pancreatic carcinoma: implications for tumor vaccines. Cancer Immunology, Immunotherapy : Cii. 51: 327-40. PMID 12111121 DOI: 10.1007/S00262-002-0277-3  0.625
1998 Tempero RM, VanLith ML, Morikane K, Rowse GJ, Gendler SJ, Hollingsworth MA. CD4+ lymphocytes provide MUC1-specific tumor immunity in vivo that is undetectable in vitro and is absent in MUC1 transgenic mice. Journal of Immunology (Baltimore, Md. : 1950). 161: 5500-6. PMID 9820526  0.772
1998 Rowse GJ, Tempero RM, VanLith ML, Hollingsworth MA, Gendler SJ. Tolerance and immunity to MUC1 in a human MUC1 transgenic murine model. Cancer Research. 58: 315-21. PMID 9443411  0.692
1998 VanLith ML, Tempero RM, Gendler SJ, Hollingsworth MA. In vitro kinetic analysis of cellular anti-MUC1 immune responses in MUC1 transgenic mice Faseb Journal. 12: A891.  0.693
1998 Tempero RM, Morikane K, Vanlith ML, Gendler SJ, Hollingsworth MA. Tolerance and immunity to MUC1 in a human MUC1 transgenic murine model Faseb Journal. 12: A891.  0.792
Show low-probability matches.